Guillain-Barre Syndrome Market Set for Robust Growth Through 2034, Driven by Advancements in Clinical Development Pipeline | DelveInsight

The Guillain-Barre Syndrome market is experiencing significant expansion, driven by increasing disease awareness, rising prevalence, and breakthrough therapies from key pharmaceutical players, including Annexon, Hansa Biopharma, Alexion Pharmaceuticals, and others. There is currently no FDA-approved drug specifically for Guillain-Barre syndrome, creating substantial opportunities for emerging therapies.
DelveInsight's "Guillain-Barre Syndrome Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr]" report delivers an in-depth understanding of the Guillain-Barre Syndrome treatment market, historical and forecasted epidemiology, as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report comprehensively evaluates the current treatment landscape, emerging therapies, market share of individual treatments, and GBS market forecasts through 2034, providing crucial insights for stakeholders in the Guillain-Barre Syndrome therapeutic area.

Guillain-Barre Syndrome Market Outlook

According to DelveInsight's analysis, the Guillain-Barre Syndrome market is expected to experience significant growth during the forecast period (2024-2034), driven by various market-driving factors such as the rising Guillain-Barre syndrome incidence, increasing awareness, the promising pipeline of innovative treatment options, and increased investment by pharmaceutical companies for research and development. The overall Guillain-Barre syndrome therapeutics market is expected to grow at a significant CAGR over the forecast period due to the anticipated approval of emerging therapies under development.

Furthermore, the United States holds a significant share of the overall 7MM Guillain-Barre syndrome market, primarily attributed to the country's higher occurrence of the condition and the elevated cost of available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Download the Guillain-Barre Syndrome Market report to understand which factors are driving the GBS therapeutic market @ Guillain-Barre syndrome Market Trends [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr].

Guillain-Barre Syndrome Epidemiology

According to DelveInsight's estimates, Guillain-Barre syndrome affects about one or two people each year in every 100K population, with people of all ages being affected. Additionally, it is more common in adults and males.

In Europe and North America, Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) is the most frequent form of GBS, accounting for around 90% of cases. Furthermore, Acute motor axonal neuropathy (AMAN) affects the axons of the nerves going to the muscles and is the most common form in some Asian countries.

The DelveInsight report further categorizes the Guillain-Barre Syndrome patient population into several groups for analysis. It differentiates between three different forms of GBS: Acute inflammatory demyelinating polyradiculoneuropathy (AIDP), which predominantly affects the myelin and is the most common form in America and Europe; Acute motor axonal neuropathy (AMAN), which affects the axons of nerves going to muscles and is most common in some Asian countries; and Acute motor and sensory axonal neuropathy (AMSAN), which affects the axons of both motor and sensory nerves. This classification is essential for understanding the distribution, progression, and treatment responses of different GBS types and is crucial for accurate epidemiological assessment.

Discover evolving trends in the Guillain-Barre Syndrome patient pool forecasts @ Guillain-Barre Syndrome Epidemiology Analysis [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr].

Guillain-Barre Syndrome Treatment Landscape

While there is no definitive cure for GBS, several treatment options are aimed at Guillain-Barre Syndrome management. The predominant treatment for Guillain-Barre Syndrome patients is intravenous immunoglobulin (IVIG), which works by blocking the effects of harmful antibodies, and plasma exchange (PE) therapy, which removes harmful substances, including antibodies that cause GBS. IVIG is more convenient and more widely available than PE, but both are equally helpful. Early treatment within the first 2 weeks after symptom onset is preferable.

According to the DelveInsight report, the Guillain-Barre Syndrome therapies pipeline is promising, with several novel treatments in development. ANX005 by Annexon is a clinical-stage investigational monoclonal antibody intended to treat patients with antibody-mediated autoimmune and complement-mediated neurodegenerative disorders. This novel therapy is formulated for IV administration and is designed to inhibit C1q and the entire classical complement pathway. The drug has received both fast-track and orphan drug designations from the FDA for Guillain-Barre Syndrome treatment.

Similarly, Imlifidase by Hansa Biopharma is an antibody-cleaving enzyme that specifically targets IgG and inhibits IgG-mediated immune response. Based on the positive Phase 2 results and an indirect comparison with the International Guillain-Barre Syndrome Outcome Study (IGOS), Hansa Biopharma is considering the next steps for imlifidase in GBS treatment. The drug has also been granted orphan drug designation by the US FDA.

Efgartigimod (arGEN-X) and Eculizumab (Alexion Pharmaceuticals) are also advancing rapidly through clinical trials for Guillain-Barre Syndrome, with expected further clinical trials and FDA approvals soon.

Guillain-Barre Syndrome Recent Developments

Recent developments highlight the dynamic nature of the Guillain-Barre Syndrome treatment landscape. ANX005 (Annexon, Inc.) continues to show promise in Guillain-Barre Syndrome Phase 3 clinical trials. Positive results were presented at the 2025 American Academy of Neurology (AAN) Annual Meeting in April 2025. ANX005 has received FDA Fast Track and Orphan Drug designations, with plans to submit a BLA in the first half of 2025.

Efgartigimod (arGEN-X), an FcRn blocker, is being evaluated in a Phase 3 trial (NCT05701189) for GBS. The last update was submitted in March 2025, showing positive results. The Phase 2 study results of Imlifidase in Guillain-Barre Syndrome patients were also highlighted at the 2025 PNS Annual Meeting in May 2025. The study showed promising results, demonstrating rapid improvement in muscle strength and walking ability.

In January 2025, the FDA mandated safety label changes for Pfizer's ABRYSVO and GlaxoSmithKline Biologicals' AREXVY (Respiratory Syncytial Virus Vaccines) to include a warning about a potential increased risk of GBS during the 42 days following vaccination. The FDA's decision was based on postmarketing observational studies and reports, although the available evidence is currently insufficient to establish a causal relationship.

Discover recent advancements in the Guillain-Barre Syndrome treatment landscape @ Guillain-Barre Syndrome Recent Developments [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr].

The Guillain-Barre syndrome treatment market is highly competitive, with major players including Annexon, Hansa Biopharma, Alexion Pharmaceuticals, and others, all advancing a variety of therapies through robust R&D and strategic collaborations.

Looking ahead, the GBS market is expected to witness continued innovation driven by enhanced understanding of disease mechanisms and the development of targeted therapies. While significant progress has been made with immunomodulatory treatments, challenges remain in addressing the limited availability of effective treatments, the limited understanding of causes, and the lack of awareness. Scientists are concentrating on finding new treatments and refining existing ones, with ongoing research and continued dedication offering hope for even more effective treatments and ultimately a cure for this challenging condition.

DelveInsight's analysis underscores that substantial opportunities remain for developing more effective, convenient, and affordable treatment options that can achieve better outcomes and improved quality of life for Guillain-Barre syndrome patients worldwide. As research continues and awareness grows, the Guillain-Barre syndrome market is poised for remarkable expansion and therapeutic innovation in the coming decade.

Table of Contents

1. Key Insights

2. Executive Summary of Guillain-Barre Syndrome

3. Competitive Intelligence Analysis for Guillain-Barre Syndrome

4. Guillain-Barre Syndrome Market Overview at a Glance

5. Guillain-Barre Syndrome: Disease Background and Overview

6. Guillain-Barre Syndrome Patient Journey

7. Guillain-Barre Syndrome Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Guillain-Barre Syndrome Unmet Needs

10. Key Endpoints of Guillain-Barre Syndrome Treatment

11. Guillain-Barre Syndrome Emerging Therapies

12. Guillain-Barre Syndrome: Seven Major Market Analysis

13. Attribute analysis

14. 7MM: Market Outlook

15. Access and Reimbursement Overview of Guillain-Barre Syndrome

16. KOL Views

17. Guillain-Barre Syndrome Market Drivers

18. Guillain-Barre Syndrome Market Barriers

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Related Reports

Guillain-Barre Syndrome Pipeline Insight [https://www.delveinsight.com/sample-request/guillain-barre-syndrome-pipeline-insight?utm_source=linkedin&utm_medium=promotion&utm_campaign=xpr]

Guillain-Barre Syndrome pipeline insight provides comprehensive insights about the GBS pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Guillain-Barre Syndrome companies, including Annexon, Inc. and Hansa Biopharma, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=guillainbarre-syndrome-market-set-for-robust-growth-through-2034-driven-by-advancements-in-clinical-development-pipeline-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.